Renal artery stenosis resident survival guide

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernandez, M.D. [2]

Definition

This section provides a short and straight to the point definition of the disease or symptom in one sentence.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Clinical Clues to the Diagnosis of RAS

 
 
Determine if one or more of the above is present
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ScenarioLevel of evidence
1.Onset of hypertension before the age of 30 years or severe hypertension after the age of 55Class I; LOE B
2. Accelerated, resistant, or malignant hypertensionClass I; LOE C
3. Development of new azotemia or worsening renal function after administration of an ACE inhibitor or ARB agentClass I; LOE B
4. Unexplained atrophic kidney or size discrepancy between kidneys of greater than 1.5 cmClass I; LOE B
5. Sudden, unexplained pulmonary edemaClass I; LOE B
6. Unexplained renal dysfunction, including individuals starting renal replacement therapyClass IIa; LOE B
7. Multi-vessel coronary artery diseaseClass IIb; LOE B
8. Unexplained congestive heart failureClass IIb; LOE C
9. Refractory anginaClass IIb; LOE C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proceed to further diagnostic testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noninvasive Imaging
  • Duplex ultrasound
  • Gadolinium enhanced MRA
  • CT angiography
 
Invasive Imaging
  • Abdominal aortography to assess the renal arteries during coronary and peripheral angiography
  •  
     
     
     
     
     
     
     
     
     
    ❑ Do not monitor platelet count
     
    ❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped)

    Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]



    References


    Template:WikiDoc Sources

    1. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.